Pacur To Acquire CAROLEX To Expand Global Position And Customer Reach

Pacur is the leading supplier of extruded PETG sheet used principally to provide rigid, high-performance packaging for medical devices.

Pacur, LLC, a market leading supplier of specialty plastic packaging materials for the medical device industry, announced today that it has signed a definitive agreement to acquire CAROLEX SAS, a polyethylene terephthalate glycol (“PETG”) sheet extruder based in France. The acquisition strengthens Pacur’s medical device focus in Europe and extrusion capabilities to meet the global demands of customers.

Pacur is the leading supplier of extruded PETG sheet used principally to provide rigid, high-performance packaging for medical devices. The company also produces sheet for certain specialty graphics, pharmaceutical packaging, and food packaging applications.

CAROLEX represents Pacur’s first acquisition and extends the company’s best-in-class customer service and reputation for quality into Europe. Oshkosh, WI-based Pacur is acquiring CAROLEX from epsotech Holding GmbH, a supplier of primarily thick gauge extruded plastic sheet with seven other factories in Europe. Pacur is a portfolio company of middle-market private equity firm Gryphon Investors, which invested in Pacur in 2020. Terms of the transaction, which is expected to close by year end, were not disclosed.

The CAROLEX management team will remain in place, led by Managing Director Sylvain Forestier.

John Carlson, CEO of Pacur said, “The past two years have certainly highlighted how important the entire medical supply chain has become, and has reinforced Pacur’s commitment to increasing our global presence. We are excited to join forces with Sylvain and the entire CAROLEX team and to develop a strong partnership in technology and customer satisfaction. We look forward to investing in Carolex and bringing Pacur’s market-leading capabilities in product innovation to Carolex’s European customers.”

Mr. Forestier commented, “We are delighted to become part of a top-notch global supplier. Under epsotech, we strengthened our production capacity and developed a world-class service capability, and we are now eager to join Pacur to support our next phase of growth. We look forward to continuing our commitment to innovation and leadership and gaining increased resources to better serve our customers.”

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.